Notably, PAX5 loss increases c-myc expression and proliferation in B-ALL, opening the possibility to consider c-myc as a novel, potentially highly effective target against childhood B-ALL overexpressing c-myc and harboring PAX5 rearrangements and mutations. The gene discussed is MYC; the disease is precursor B-cell acute lymphoblastic leukemia.